Publicaciones en colaboración con investigadores/as de Instituto de Salud Carlos III (22)

2024

  1. Caspases compromise SLU7 and UPF1 stability and NMD activity during hepatocarcinogenesis

    JHEP Reports, Vol. 6, Núm. 8

  2. Systemic messenger RNA replacement therapy is effective in a novel clinically relevant model of acute intermittent porphyria developed in non-human primates

    Gut

2023

  1. Frontiers in fatty liver: recent advances in pathogenic mechanisms, assessment of patients’ prognosis and pharmacotherapy: MASLD: new pathogenic mechanisms, risk assessment tools and drug therapies

    Journal of Physiology and Biochemistry

  2. Loss of liver function in chronic liver disease: An identity crisis

    Journal of Hepatology, Vol. 78, Núm. 2, pp. 401-414

2022

  1. Bile Processing Protocol for Improved Proteomic Analysis

    Methods in Molecular Biology (Humana Press Inc.), pp. 1-10

  2. Immunogenomic classification of hepatocellular carcinoma patients for immune check-point inhibitors therapy: Cui bono ?

    Gut

  3. Impact of CYLD on chromatin structure and histone methylation in malignant melanoma

    International Journal of Molecular Medicine, Vol. 49, Núm. 5

  4. New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogramming

    Journal of Experimental and Clinical Cancer Research, Vol. 41, Núm. 1

2021

  1. Armcx3 mediates susceptibility to hepatic tumorigenesis promoted by dietary lipotoxicity

    Cancers, Vol. 13, Núm. 5, pp. 1-22

  2. Digging deeper into bile proteome

    Journal of Proteomics, Vol. 230

  3. FOSL1 promotes cholangiocarcinoma via transcriptional effectors that could be therapeutically targeted

    Journal of Hepatology, Vol. 75, Núm. 2, pp. 363-376

  4. Neddylation inhibition ameliorates steatosis in NAFLD by boosting hepatic fatty acid oxidation via the DEPTOR-mTOR axis

    Molecular Metabolism, Vol. 53

  5. The splicing regulator SLU7 is required to preserve DNMT1 protein stability and DNA methylation

    Nucleic Acids Research, Vol. 49, Núm. 15, pp. 8592-8609

  6. mRNA-based therapy in a rabbit model of variegate porphyria offers new insights into the pathogenesis of acute attacks

    Molecular Therapy - Nucleic Acids, Vol. 25, pp. 207-219

2019

  1. Epigenetic events involved in organic cation transporter 1-dependent impaired response of hepatocellular carcinoma to sorafenib

    British Journal of Pharmacology, Vol. 176, Núm. 6, pp. 787-800

  2. Messenger RNA therapy for rare genetic metabolic diseases

    Gut, Vol. 68, Núm. 7, pp. 1323-1330

2018

  1. Fibroblast growth factors 19 and 21 in acute liver damage

    Annals of Translational Medicine, Vol. 6, Núm. 12, pp. 257

  2. Systemic messenger RNA as an etiological treatment for acute intermittent porphyria

    Nature Medicine, Vol. 24, Núm. 12, pp. 1899-1909

2016

  1. Further evidence on the janus-faced nature of the epidermal growth factor receptor: From liver regeneration to hepatocarcinogenesis

    Hepatology, Vol. 63, Núm. 2, pp. 371-374

2015

  1. Making sorafenib irresistible: In vivo screening for mechanisms of therapy resistance in hepatocellular carcinoma hits on Mapk14

    Hepatology, Vol. 61, Núm. 5, pp. 1755-1757